Jeeshitha M, Maikap Debashis, Padhan Prasanta, Mishra Jayanti, Singh Pratima
Department of Pulmonary Medicine, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.
Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.
Mediterr J Rheumatol. 2024 Dec 31;35(4):617-622. doi: 10.31138/mjr.260423.pof. eCollection 2024 Dec.
Sarcopenia, a progressive loss of skeletal muscle strength and mass, can lead to decreased quality of life, physical disability, and mortality. Early identification of sarcopenia is crucial in limiting morbidity and mortality in connective tissue disease associated interstitial lung diseases (CTDILD) patients.
The objectives of this study are to determine the prevalence of sarcopenia in CTD-ILD patients and to correlate the severity of sarcopenia with pulmonary function tests, spirometry, and 6-minute walk test (6MWT).
The study involved 32 CTD-ILD patients, documenting their demographic, clinical, and medical history, and conducting various tests, including spirometry, 6MWT, ANA, ENA, MSA profile, and HRCT thorax. Sarcopenia was evaluated using the SARC-F questionnaire, while muscle mass, strength, and physical performance were assessed using the BODYSTAT Quad scan 4000, chair stand test, and gait speed test.
Pre-sarcopenia was the most common condition, followed by sarcopenia and severe sarcopenia. MCTD-ILD and SSc-ILD were the most commonly observed types of CTD-ILD. Patients with pre-sarcopenia had the highest mean FVC, FEV1 (in litres), FVC (%) and FEV1 (%) compared to patients with sarcopenia. The mean distance walked in 6MWT was lowest in patients with severe sarcopenia and highest in patients with sarcopenia, but the difference was not statistically significant.
This study highlights a higher prevalence of sarcopenia in CTD-ILD patients, and its effects on lung function and physical performance. Early identification and intervention for sarcopenia could improve the quality of life and survival in these patients.
肌肉减少症是骨骼肌力量和质量的渐进性丧失，可导致生活质量下降、身体残疾和死亡。早期识别肌肉减少症对于限制结缔组织病相关间质性肺病（CTDILD）患者的发病率和死亡率至关重要。
本研究的目的是确定CTD-ILD患者中肌肉减少症的患病率，并将肌肉减少症的严重程度与肺功能测试、肺活量测定和6分钟步行试验（6MWT）相关联。
该研究纳入了32例CTD-ILD患者，记录他们的人口统计学、临床和病史，并进行各种测试，包括肺活量测定、6MWT、抗核抗体（ANA）、可提取核抗原（ENA）、微卫星分析（MSA）谱和胸部高分辨率CT（HRCT）。使用SARC-F问卷评估肌肉减少症，同时使用BODYSTAT Quad scan 4000、椅子站立试验和步态速度试验评估肌肉质量、力量和身体表现。
肌少症前期是最常见的情况，其次是肌肉减少症和严重肌肉减少症。混合性结缔组织病相关间质性肺病（MCTD-ILD）和系统性硬化症相关间质性肺病（SSc-ILD）是最常见的CTD-ILD类型。与肌肉减少症患者相比，肌少症前期患者的平均用力肺活量（FVC）、第一秒用力呼气容积（FEV1，以升为单位）、FVC（%）和FEV1（%）最高。在6MWT中，严重肌肉减少症患者行走的平均距离最低，肌肉减少症患者最高，但差异无统计学意义。
本研究强调CTD-ILD患者中肌肉减少症的患病率较高，及其对肺功能和身体表现的影响。早期识别和干预肌肉减少症可改善这些患者的生活质量和生存率。
